FY2029 Earnings Estimate for PepGen Issued By HC Wainwright

PepGen Inc. (NASDAQ:PEPG) – Analysts at HC Wainwright issued their FY2029 EPS estimates for shares of PepGen in a research report issued on Thursday, January 30th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.21) per share for the year. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.21.

Other research analysts have also issued research reports about the company. Wedbush cut their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a report on Monday, December 16th.

PepGen Stock Performance

PepGen stock opened at $1.44 on Friday. The business has a 50-day simple moving average of $3.83 and a 200 day simple moving average of $7.50. PepGen has a 52 week low of $1.42 and a 52 week high of $19.30.

Institutional Trading of PepGen

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its stake in shares of PepGen by 331.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after purchasing an additional 1,794,641 shares in the last quarter. Suvretta Capital Management LLC lifted its stake in PepGen by 9.2% in the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after purchasing an additional 140,000 shares during the last quarter. Walleye Capital LLC purchased a new stake in PepGen during the third quarter valued at about $519,000. Wellington Management Group LLP grew its stake in shares of PepGen by 76.9% during the third quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock valued at $346,000 after buying an additional 17,618 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of PepGen by 29.1% in the third quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock worth $237,000 after buying an additional 6,254 shares during the period. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.